Chronic Ischemic Heart Disease Clinical Trial
Official title:
68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Angiogenesis in Ischemic Heart Disease
The aim is to examine the expression of αvβ3 integrin using a novel selective radiotracer in patients with chronich ischemic heart disease and investigate if it is a suitable tool for predicting myocardial recovery and thus prognosis after intervention.
Ischemic heart disease is worldwide the single most frequent cause of death. The number of patients surviving acute myocardial injury is increasing due to improved acute treatment. However, after the initial repair, the tissue undergoes a remodeling phase to compensate for the damaged area. This re-modeling phase can change the structure end geometry of the heart resulting in lower ejection fraction, leading to cardiac dysfunction, which eventually leads to heart failure. Ischemic heart disease is most commently caused by arteriosclerosis of the coronary artery. If chronic ischemic heart disease is left untreated, it will lead to symptoms to the patient. These symptons occur when the myocardiel oxygen demand exceeds the oxygen provided, due to coronary occlusion. If the heart suffers from ischemia, the tissue reacts strongly to the hypoxia. The body will as a compensatory mechanism create new vessel to provide the tissue with oxygen. This is known as the biological process of angiogenesis. This complex process involves different angiogenic and pro-fibrotic transcription factors that initiate the restoration of capillaries by sprouting from the existing endothelial cells in response to hypoxia. Integrin αvβ3 is a transmembrane cell surface receptor that is markedly upregulated in states of angiogenesis. It facilitates migration and proliferation and thereby allowing cells to respond to extracellular environment. Integrin αvβ3 is thus a key player in the angiogenic process. The integrin αvβ3 has a binding site for an RGD peptide (Arg-Gly-Asp motif) and this can be targeted by PET tracers. RGD-based PET tracers have been shown to accumulate at the site of myocardial necrosis in both human and animal studies. The uptake before interventions may correlate to recovery of cardiac function and thus serve as a prognostic marker after intervention. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03809689 -
Study of Cardiac Lesions Angiogenesis by 68Ga-NODAGA-RGD Cardiac PET
|
N/A | |
| Recruiting |
NCT02439541 -
Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Ischemic Cardiomyopathy
|
Phase 1/Phase 2 | |
| Completed |
NCT04916912 -
Results of Coronary Artery Bypass Grafting in Obese Patients
|
||
| Completed |
NCT00824005 -
Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study)
|
Phase 2 | |
| Completed |
NCT03796741 -
STable Coronary Artery Diseases RegisTry
|
||
| Completed |
NCT03043742 -
Stem Cell Heart Injections During Laser Revascularization Surgery for Treatment of Chronic Ischemic Heart Disease
|
Phase 1 | |
| Terminated |
NCT01666132 -
METHOD - Bone Marrow Derived Mononuclear Cells in Chronic Ischemic Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT01727063 -
Cell Therapy in Severe Chronic Ischemic Heart Disease
|
Phase 3 | |
| Completed |
NCT01449032 -
MesenchYmal STROMAL CELL Therapy in Patients With Chronic Myocardial Ischemia (MyStromalCell Trial)
|
Phase 2 |